The 144-page US Senate report on Gilead's pricing practices is the latest in a chorus of criticisms launched against big pharmaceuticals. The committee overseeing the overpricing by Gilead focused on their drug Sovaldi and its partner treatment Harvoni.
"It was always Gilead's plan to maximize revenue, and affordability and accessibility was an afterthought," Democrat Senator Ron Wyden from Oregon said at a news conference together with Republican Iowa Senator Chuck Grassley. …show more content…
The $11 billion Gilead paid for Pharmasset to acquire the medications was “purely a desire to maximize